News > Pharmaceuticals

11th July 2016

BIA response to the announcement from Business Secretary Sajid Javid for £10 million for the Biomedical Catalyst 2016

BIA Chief Executive, Steve Bates, has responded to Business Secretary Sajid Javid’s announcement of £10 million of funding for the Biomedical Catalyst 2016, which will be administered by Innovate UK. The Biomedical Catalyst 2016 is being funded by Innovate UK, MRC and Scottish Enterprise. Applications for the early stage award and feasibility study award are…

24th June 2016

Orphan Drug Designation granted to Neem Biotech’s lead drug candidate for the treatment of Pseudomonas aeruginosa lung infections in CF patients

Neem Biotech’s lead candidate NX-AS-401 has recently received Orphan Drug Designation from the United States FDA for treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. This is a significant boost for the ongoing development of Neem’s flagship candidate drug substance. The outcome of an application for Orphan Drug Designation from the European Medicine…

27th May 2016

BIA launches briefing paper on orphan medicinal products to coincide with European Conference on Rare Diseases & Orphan Products

BIA launches briefing paper on orphan medicinal products to coincide with European Conference on Rare Diseases & Orphan Products The BIA has today launched a new briefing paper on Orphan Medicinal Products that looks into the 15 year application of the Orphan Regulation in Europe. The launch of the paper coincides with the European Conference…

19th May 2016

PCI Pharma Services welcomes Pieter-Jan Vos as Business Development Manager in its international sales team

Leading pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Pieter-Jan Vos as Business Development Manager in its International Clinical Services division, with responsibility for Germany, The Netherlands and Switzerland. As part of the established International Business Development Team, Pieter-Jan joins PCI Clinical Services to support clients with a full suite of…

16th May 2016

PCI congratulates Vertex and Mannkind for Compliance Package of the Year Awards

Healthcare Compliance Packaging Council (HCPC) Announces Compliance Packages of the Year HCPC 2015 Compliance Package of the Year: Vertex ORKAMBI® Medication Package HCPC 2015 Compliance Package of the Year Second Runner-Up: MannKind Afrezza® Medication Package PCI is proud to congratulate Vertex and MannKind for their recent awards in the Healthcare Compliance Packaging Council’s 2015 Compliance…

10th May 2016

Expert advice from Geldards LLP: The general data protection regulation – how will businesses in the life sciences sector be affected?

The countdown to the General Data Protection Regulation 2016 (“GDPR”) has finally begun! It has now been published in the EU Official Journal and will automatically apply in all member states (without the need for national implementing legislation) from 25th May 2018. It will repeal the Data Protection Directive 1995 (“DPD”) and the national data…

10th May 2016

OncoTherics is raising investment to pursue a Phase II trial in pancreatic cancer

OncoTherics is raising investment to pursue a Phase II trial in pancreatic cancer with its new and exciting prodrug therapies. The company has entered the VOOM 2016 competition and need your votes – click here to add your support. The goal for OncoTherics is to develop new drugs that target areas of the tumour that conventional…

09th May 2016

Quay Pharma is awarded Eurostars funding for oncology project

Pharmaceutical outsourcing specialist Quay Pharma is working on a new therapy for solid tumours, for example breast cancer, as part of the EU-funded Eurostars scheme. Eurostars supports international innovative projects led by SME (small and medium-sized enterprises) research and development companies throughout Europe. It brings together organisations with varying expertise from different countries to combine…

09th May 2016

MHRA approval of Quay Pharma’s GMP manufacturing suites

Pharmaceutical outsourcing specialist Quay Pharma has received full MHRA approval for its newly-installed GMP manufacturing suites at its headquarters in Deeside. The new suites are part of a £3 million investment which has increased the company’s overall manufacturing capacity and enabled it to make larger batches of product in order to continue support through Phase…

04th May 2016

Moleculomics identifies novel host-pathogen interaction drug targets

Moleculomics, a company who specialises in high-throughput prediction of molecular interactions using cutting-edge in silico modelling and screening tools, has recently completed a project funded by the Defence Science and Technology Laboratory’s (Dstl) Centre for Defence Enterprise (CDE). It focuses on the identification of host-pathogen interactions which can be manipulated in order to devise novel…